Contemporary surgical treatment of advanced-stage melanoma

Richard Essner, Jonathan H. Lee, Leslie A. Wanek, Hitoe Itakura, Donald L. Morton, Roy E. Coats, Jan H. Wong, Stanley P L Leong, James E. Goodnight

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Hypothesis: The clinical treatment of patients with stage IV melanoma according to criteria of the American Joint Committee on Cancer (AJCC) is controversial because the 5-year survival rate is approximately 5%. Specific clinicopathologic factors are predictive of survival following curative surgery. Design: Cohort analysis of 1574 successive patients undergoing surgical resection of metastatic melanoma for a 29-year period. Patients received follow-up on a routine basis with serial examinations and radiographic studies. The median follow-up time was 19 months (range, 1-382 months). Setting: Tertiary cancer center. Patients. Surgical resection was performed in 1574 patients. The decision to perform surgery was individualized for each patient. Interventions The technique of surgical resection was based on the site of metastasis. Main Outcome Measure: Computer-assisted database with statistical analyses using log-rank tests and Cox regression models. Results: Of the 4426 patients with AJCC stage IV melanoma, 1574 (35%) underwent surgical resection; 970 (62%) were men, with a median age of 50 years. Of the primary melanomas, 46% arose on the trunk, and 56% were Clark level IV or V with a median thickness of 2.2 mm. We found 697 patients (44%) to have AJCC stage III melanoma (lymph node) prior to the development of stage IV metastases. The most common site for resection was the lung (42%), followed by the skin or lymph node (19%) and the alimentary tract (16%). Of our patients, 877 (56%) had melanoma at a single site. The 5-year survival rate was significantly (P<.001) better for patients with a solitary melanoma (mean ± SD, 29% ± 2%) than those with 4 or more metastases (n = 147; mean ± SD, 11% ± 3%). Skin and lymph node metastases had the most favorable survival rate (median, 35.1 months). Multivariate analyses identified an earlier primary tumor stage (I vs II) (P<.001), an absence of intervening stage III metastases (P = .02), solitary metastasis (P<.001), and a long (>36 months) disease-free interval from AJCC stage I or II to stage IV (P = .005) as predictive of survival. Conclusions: Our results demonstrate the benefit of surgical resection for advanced-stage melanoma. Patients with limited sites and numbers of metastases should be considered for curative resection regardless of the location of the disease.

Original languageEnglish (US)
Pages (from-to)961-967
Number of pages7
JournalArchives of Surgery
Volume139
Issue number9
DOIs
StatePublished - Sep 2004

Fingerprint

Melanoma
Therapeutics
Neoplasms
Neoplasm Metastasis
Survival Rate
Lymph Nodes
Survival
Proportional Hazards Models
Cohort Studies
Outcome Assessment (Health Care)
Databases
Lung
Skin

ASJC Scopus subject areas

  • Surgery

Cite this

Essner, R., Lee, J. H., Wanek, L. A., Itakura, H., Morton, D. L., Coats, R. E., ... Goodnight, J. E. (2004). Contemporary surgical treatment of advanced-stage melanoma. Archives of Surgery, 139(9), 961-967. https://doi.org/10.1001/archsurg.139.9.961

Contemporary surgical treatment of advanced-stage melanoma. / Essner, Richard; Lee, Jonathan H.; Wanek, Leslie A.; Itakura, Hitoe; Morton, Donald L.; Coats, Roy E.; Wong, Jan H.; Leong, Stanley P L; Goodnight, James E.

In: Archives of Surgery, Vol. 139, No. 9, 09.2004, p. 961-967.

Research output: Contribution to journalArticle

Essner, R, Lee, JH, Wanek, LA, Itakura, H, Morton, DL, Coats, RE, Wong, JH, Leong, SPL & Goodnight, JE 2004, 'Contemporary surgical treatment of advanced-stage melanoma', Archives of Surgery, vol. 139, no. 9, pp. 961-967. https://doi.org/10.1001/archsurg.139.9.961
Essner R, Lee JH, Wanek LA, Itakura H, Morton DL, Coats RE et al. Contemporary surgical treatment of advanced-stage melanoma. Archives of Surgery. 2004 Sep;139(9):961-967. https://doi.org/10.1001/archsurg.139.9.961
Essner, Richard ; Lee, Jonathan H. ; Wanek, Leslie A. ; Itakura, Hitoe ; Morton, Donald L. ; Coats, Roy E. ; Wong, Jan H. ; Leong, Stanley P L ; Goodnight, James E. / Contemporary surgical treatment of advanced-stage melanoma. In: Archives of Surgery. 2004 ; Vol. 139, No. 9. pp. 961-967.
@article{9ba2b7207d62411abcc5638b6873fba9,
title = "Contemporary surgical treatment of advanced-stage melanoma",
abstract = "Hypothesis: The clinical treatment of patients with stage IV melanoma according to criteria of the American Joint Committee on Cancer (AJCC) is controversial because the 5-year survival rate is approximately 5{\%}. Specific clinicopathologic factors are predictive of survival following curative surgery. Design: Cohort analysis of 1574 successive patients undergoing surgical resection of metastatic melanoma for a 29-year period. Patients received follow-up on a routine basis with serial examinations and radiographic studies. The median follow-up time was 19 months (range, 1-382 months). Setting: Tertiary cancer center. Patients. Surgical resection was performed in 1574 patients. The decision to perform surgery was individualized for each patient. Interventions The technique of surgical resection was based on the site of metastasis. Main Outcome Measure: Computer-assisted database with statistical analyses using log-rank tests and Cox regression models. Results: Of the 4426 patients with AJCC stage IV melanoma, 1574 (35{\%}) underwent surgical resection; 970 (62{\%}) were men, with a median age of 50 years. Of the primary melanomas, 46{\%} arose on the trunk, and 56{\%} were Clark level IV or V with a median thickness of 2.2 mm. We found 697 patients (44{\%}) to have AJCC stage III melanoma (lymph node) prior to the development of stage IV metastases. The most common site for resection was the lung (42{\%}), followed by the skin or lymph node (19{\%}) and the alimentary tract (16{\%}). Of our patients, 877 (56{\%}) had melanoma at a single site. The 5-year survival rate was significantly (P<.001) better for patients with a solitary melanoma (mean ± SD, 29{\%} ± 2{\%}) than those with 4 or more metastases (n = 147; mean ± SD, 11{\%} ± 3{\%}). Skin and lymph node metastases had the most favorable survival rate (median, 35.1 months). Multivariate analyses identified an earlier primary tumor stage (I vs II) (P<.001), an absence of intervening stage III metastases (P = .02), solitary metastasis (P<.001), and a long (>36 months) disease-free interval from AJCC stage I or II to stage IV (P = .005) as predictive of survival. Conclusions: Our results demonstrate the benefit of surgical resection for advanced-stage melanoma. Patients with limited sites and numbers of metastases should be considered for curative resection regardless of the location of the disease.",
author = "Richard Essner and Lee, {Jonathan H.} and Wanek, {Leslie A.} and Hitoe Itakura and Morton, {Donald L.} and Coats, {Roy E.} and Wong, {Jan H.} and Leong, {Stanley P L} and Goodnight, {James E.}",
year = "2004",
month = "9",
doi = "10.1001/archsurg.139.9.961",
language = "English (US)",
volume = "139",
pages = "961--967",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Contemporary surgical treatment of advanced-stage melanoma

AU - Essner, Richard

AU - Lee, Jonathan H.

AU - Wanek, Leslie A.

AU - Itakura, Hitoe

AU - Morton, Donald L.

AU - Coats, Roy E.

AU - Wong, Jan H.

AU - Leong, Stanley P L

AU - Goodnight, James E.

PY - 2004/9

Y1 - 2004/9

N2 - Hypothesis: The clinical treatment of patients with stage IV melanoma according to criteria of the American Joint Committee on Cancer (AJCC) is controversial because the 5-year survival rate is approximately 5%. Specific clinicopathologic factors are predictive of survival following curative surgery. Design: Cohort analysis of 1574 successive patients undergoing surgical resection of metastatic melanoma for a 29-year period. Patients received follow-up on a routine basis with serial examinations and radiographic studies. The median follow-up time was 19 months (range, 1-382 months). Setting: Tertiary cancer center. Patients. Surgical resection was performed in 1574 patients. The decision to perform surgery was individualized for each patient. Interventions The technique of surgical resection was based on the site of metastasis. Main Outcome Measure: Computer-assisted database with statistical analyses using log-rank tests and Cox regression models. Results: Of the 4426 patients with AJCC stage IV melanoma, 1574 (35%) underwent surgical resection; 970 (62%) were men, with a median age of 50 years. Of the primary melanomas, 46% arose on the trunk, and 56% were Clark level IV or V with a median thickness of 2.2 mm. We found 697 patients (44%) to have AJCC stage III melanoma (lymph node) prior to the development of stage IV metastases. The most common site for resection was the lung (42%), followed by the skin or lymph node (19%) and the alimentary tract (16%). Of our patients, 877 (56%) had melanoma at a single site. The 5-year survival rate was significantly (P<.001) better for patients with a solitary melanoma (mean ± SD, 29% ± 2%) than those with 4 or more metastases (n = 147; mean ± SD, 11% ± 3%). Skin and lymph node metastases had the most favorable survival rate (median, 35.1 months). Multivariate analyses identified an earlier primary tumor stage (I vs II) (P<.001), an absence of intervening stage III metastases (P = .02), solitary metastasis (P<.001), and a long (>36 months) disease-free interval from AJCC stage I or II to stage IV (P = .005) as predictive of survival. Conclusions: Our results demonstrate the benefit of surgical resection for advanced-stage melanoma. Patients with limited sites and numbers of metastases should be considered for curative resection regardless of the location of the disease.

AB - Hypothesis: The clinical treatment of patients with stage IV melanoma according to criteria of the American Joint Committee on Cancer (AJCC) is controversial because the 5-year survival rate is approximately 5%. Specific clinicopathologic factors are predictive of survival following curative surgery. Design: Cohort analysis of 1574 successive patients undergoing surgical resection of metastatic melanoma for a 29-year period. Patients received follow-up on a routine basis with serial examinations and radiographic studies. The median follow-up time was 19 months (range, 1-382 months). Setting: Tertiary cancer center. Patients. Surgical resection was performed in 1574 patients. The decision to perform surgery was individualized for each patient. Interventions The technique of surgical resection was based on the site of metastasis. Main Outcome Measure: Computer-assisted database with statistical analyses using log-rank tests and Cox regression models. Results: Of the 4426 patients with AJCC stage IV melanoma, 1574 (35%) underwent surgical resection; 970 (62%) were men, with a median age of 50 years. Of the primary melanomas, 46% arose on the trunk, and 56% were Clark level IV or V with a median thickness of 2.2 mm. We found 697 patients (44%) to have AJCC stage III melanoma (lymph node) prior to the development of stage IV metastases. The most common site for resection was the lung (42%), followed by the skin or lymph node (19%) and the alimentary tract (16%). Of our patients, 877 (56%) had melanoma at a single site. The 5-year survival rate was significantly (P<.001) better for patients with a solitary melanoma (mean ± SD, 29% ± 2%) than those with 4 or more metastases (n = 147; mean ± SD, 11% ± 3%). Skin and lymph node metastases had the most favorable survival rate (median, 35.1 months). Multivariate analyses identified an earlier primary tumor stage (I vs II) (P<.001), an absence of intervening stage III metastases (P = .02), solitary metastasis (P<.001), and a long (>36 months) disease-free interval from AJCC stage I or II to stage IV (P = .005) as predictive of survival. Conclusions: Our results demonstrate the benefit of surgical resection for advanced-stage melanoma. Patients with limited sites and numbers of metastases should be considered for curative resection regardless of the location of the disease.

UR - http://www.scopus.com/inward/record.url?scp=4444370752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444370752&partnerID=8YFLogxK

U2 - 10.1001/archsurg.139.9.961

DO - 10.1001/archsurg.139.9.961

M3 - Article

C2 - 15381613

AN - SCOPUS:4444370752

VL - 139

SP - 961

EP - 967

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 9

ER -